International Journal of ADVANCED RESEARCH & INNOVATIONS
Volume 14, Issue-12
December, 2024, P27
ISSN: 2319-9253

MULTIMODAL LEARNING IN PRECISION ONCOLOGY: BRIDGING IMAGING, MOLECULAR BIOLOGY, AND CLINICAL INTELLIGENCE

[#1] **Dr. Harish Venkatesh**, Associate Professor, Department of General Medicine,
Amala Institute of Medical Sciences, Thrissur, India
Harishvenkatesh67@gmail.com

[#2]**Dr. Pooja Sinha**, Assistant Professor, Department of Microbiology,
Amala Institute of Medical Sciences, Thrissur, India
Poojasinha34@gmail.com

[#3]**Dr. Faizan Ali**, Associate Professor, Department of Community Medicine,
Amala Institute of Medical Sciences, Thrissur, India
Faizanali58@gmail.com

Abstract: Multimodal learning has emerged as one of the most transformative paradigms in precision oncology by enabling artificial intelligence (AI) systems to integrate heterogeneous biomedical data into unified computational representations that support comprehensive cancer diagnosis, prognostic prediction, therapeutic optimization, and personalized clinical decision-making. Conventional oncology frequently relies on isolated interpretation of radiological imaging, digital pathology, molecular diagnostics, and clinical information, limiting the ability to capture the complex biological interactions underlying tumor evolution and therapeutic response. Recent advances in foundation AI models, multimodal transformer architectures, graph neural networks, self-supervised learning, and generative artificial intelligence have enabled generalized representation learning across radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, electronic health records, and longitudinal clinical outcomes. These intelligent computational systems support early cancer detection, molecular characterization, biomarker discovery, prognostic prediction, therapeutic optimization, immunotherapy selection, digital twin simulation, adaptive disease monitoring, and evidence-based clinical decision support. Emerging technologies including multimodal large language models, federated learning, reinforcement learning, retrieval-augmented generation, explainable artificial intelligence, and agentic AI further strengthen multimodal oncology by enabling collaborative, privacy-preserving, transparent, and continuously adaptive biomedical intelligence. Despite remarkable technological progress, important scientific, technical, ethical, and regulatory challenges remain regarding multimodal data harmonization, computational scalability, interoperability, explainability, cybersecurity, clinical validation, and equitable implementation. This review provides a comprehensive overview of multimodal learning in precision oncology, emphasizing the integration of imaging, molecular biology, and clinical intelligence as a transformative framework for personalized cancer medicine.[1]

Keywords: *Multimodal learning, Precision oncology, Foundation models, Artificial intelligence, Radiomics, Digital pathology, Multi-omics, Clinical intelligence, Computational oncology, Personalized medicine.*

1. Introduction

Cancer is a biologically heterogeneous disease characterized by continuous genomic evolution, epigenetic remodeling, immune adaptation, metabolic reprogramming, angiogenesis, tissue remodeling, and dynamic interactions among malignant cells, stromal components, immune populations, and host physiology. These interconnected biological processes evolve throughout diagnosis, treatment, recurrence, metastasis, and survivorship, making precision oncology increasingly dependent upon computational systems capable of integrating heterogeneous biomedical information across multiple biological scales.[2]

Modern oncology routinely generates enormous quantities of biomedical information through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, physician documentation, electronic health records, and patient-reported outcomes. Although each modality contributes valuable biological insight, isolated interpretation frequently overlooks systems-level relationships governing disease progression, therapeutic response, resistance mechanisms, and long-term clinical outcomes.[3]

Artificial intelligence has emerged as a transformative computational technology capable of integrating these heterogeneous biomedical datasets into unified patient-centered representations. Multimodal learning extends these capabilities by simultaneously analyzing complementary biomedical modalities while foundation AI models enable transferable knowledge across numerous oncology applications.

The convergence of multimodal learning with precision oncology therefore establishes a transformative computational framework capable of accelerating personalized cancer diagnosis, therapeutic optimization, and clinical translation.[4]

2. Evolution of Multimodal Learning in Oncology

Artificial intelligence in oncology has evolved from isolated statistical analyses toward intelligent computational ecosystems capable of continuously learning from multimodal biomedical information. Early machine learning algorithms primarily relied upon handcrafted feature engineering and task-specific predictive models developed for individual diagnostic or prognostic applications. Although these systems demonstrated important clinical value, they remained constrained by fragmented biomedical information, limited adaptability, and narrow generalizability.[5]

Deep learning substantially transformed computational oncology through automated representation learning from radiological imaging, digital pathology, genomic sequencing, and electronic health records. Transformer architectures subsequently revolutionized biomedical artificial intelligence by enabling generalized contextual learning across heterogeneous biomedical modalities.

Foundation AI models now acquire transferable biomedical knowledge through large-scale self-supervised pretraining, enabling simultaneous integration of imaging, molecular biology, pathology, laboratory medicine, and clinical information into unified computational ecosystems supporting precision oncology.[6]

3. Principles of Multimodal Foundation Models

Multimodal foundation AI models differ fundamentally from conventional artificial intelligence because they acquire generalized biomedical representations from massive heterogeneous datasets before specialization for individual oncology applications. Rather than learning isolated predictive tasks, these models develop transferable computational knowledge applicable across diagnosis, prognosis, molecular characterization, biomarker discovery, therapeutic optimization, disease monitoring, computational pathology, radiomics, immunotherapy, and clinical decision support.[7]

Self-supervised learning enables discovery of latent biological relationships without requiring extensive manual annotation, while multimodal transformer architectures align radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, patient-reported outcomes, and longitudinal clinical trajectories within unified computational embedding spaces.

International Journal of ADVANCED RESEARCH & INNOVATIONS
Volume 14, Issue-12
December, 2024, P27
ISSN: 2319-9253

Graph neural networks further characterize interactions among genes, proteins, signaling pathways, immune populations, imaging phenotypes, tissue architecture, therapeutic targets, physiological variables, and clinical outcomes, thereby enabling systems-level computational reasoning supporting precision oncology.[8]

4. Computational Architecture

Modern multimodal oncology platforms consist of interconnected computational layers responsible for biomedical data acquisition, preprocessing, representation learning, multimodal fusion, adaptive learning, predictive analytics, digital twin simulation, and intelligent clinical decision support.[9]

The acquisition layer continuously integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language processing, synchronize temporal patient information, and establish cross-modal alignment.

Foundation AI models subsequently generate generalized multimodal embeddings representing molecular biology, tissue architecture, imaging phenotypes, physiological function, and longitudinal clinical trajectories. These unified computational representations support diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive learning, and personalized oncology.[10]

5. Imaging Intelligence

Radiological imaging provides comprehensive anatomical and functional characterization of tumors throughout diagnosis, treatment, recurrence, and surveillance. Foundation AI models automatically extract generalized imaging representations from computed tomography, magnetic resonance imaging, positron emission tomography, ultrasound, mammography, and hybrid imaging platforms without requiring handcrafted feature engineering.[11]

Artificial intelligence identifies latent imaging biomarkers associated with molecular alterations, immune infiltration, angiogenesis, fibrosis, hypoxia, therapeutic responsiveness, treatment resistance, and disease progression. Integration of radiological intelligence with molecular biology and clinical information substantially improves diagnosis, prognostic prediction, biomarker discovery, therapeutic optimization, and longitudinal disease monitoring.

These imaging representations provide a non-invasive computational window into evolving tumor biology while strengthening precision oncology throughout the patient journey.[12]

6. Molecular Biology Integration

Comprehensive molecular characterization represents one of the greatest strengths of multimodal learning. Artificial intelligence integrates genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, microbiomics, spatial biology, and single-cell sequencing into generalized molecular representations capable of characterizing evolving tumor biology across multiple organizational scales.[13]

Transformer architectures identify latent biological relationships among genes, proteins, signaling pathways, metabolites, immune responses, and therapeutic targets, while graph neural networks model complex biological interaction networks supporting systems-level computational reasoning.

These generalized molecular representations enable discovery of molecular subtypes, therapeutic biomarkers, resistance mechanisms, prognostic signatures, and novel drug targets while substantially improving individualized precision medicine.[14]

7. Digital Pathology and Histopathological Intelligence

Digital pathology provides complementary microscopic information describing cellular morphology, tissue architecture, stromal remodeling, angiogenesis, fibrosis, necrosis, immune infiltration, and spatial cellular

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1227

organization across diverse tumor types. Foundation AI models automatically extract generalized pathomic representations from whole-slide pathology images without requiring handcrafted feature engineering.[15]

Artificial intelligence identifies latent histopathological biomarkers associated with molecular alterations, immune responses, therapeutic sensitivity, disease progression, and patient survival. Integration of digital pathology with radiology, molecular biology, and clinical intelligence substantially improves systems-level understanding of tumor heterogeneity while supporting personalized precision oncology.

These integrated computational representations establish pathology as an essential component of multimodal cancer intelligence.[16]

8. Clinical Intelligence Through Electronic Health Records

Electronic health records provide one of the richest longitudinal sources of clinical intelligence available in oncology. Structured laboratory investigations, medication history, pathology reports, treatment timelines, physician documentation, hospitalizations, patient-reported outcomes, and survivorship information collectively provide comprehensive patient-level context extending beyond molecular diagnostics.[17]

Foundation AI models employ natural language processing, temporal transformers, and multimodal reasoning architectures to integrate structured and unstructured EHR data with radiology, pathology, molecular biology, laboratory biomarkers, and physiological monitoring into unified patient-specific computational representations.

These comprehensive clinical embeddings substantially improve prognostic prediction, recurrence surveillance, toxicity estimation, therapeutic optimization, survivorship management, and evidence-based clinical decision-making.[18]

9. Multimodal Precision Diagnosis and Therapeutic Prediction

One of the most clinically significant applications of multimodal learning is integrated precision diagnosis and therapeutic prediction through comprehensive fusion of imaging, molecular biology, pathology, laboratory biomarkers, wearable physiological monitoring, physician documentation, and longitudinal clinical trajectories. Foundation AI models simultaneously analyze heterogeneous biomedical information to predict responsiveness to chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations while estimating treatment-related toxicity, recurrence probability, progression-free survival, overall survival, and mechanisms of therapeutic resistance. These adaptive computational systems support individualized therapeutic planning while continuously refining predictive accuracy using newly acquired biomedical evidence throughout the cancer care continuum.[19][20]

10. Digital Twins and Multimodal Virtual Patient Modeling

Digital twin technology represents one of the most transformative applications of multimodal learning in precision oncology by creating continuously evolving virtual representations of individual cancer patients synchronized with their biological counterparts. Foundation AI models integrate serial radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, medication history, patient-reported outcomes, and longitudinal clinical information into adaptive computational patient models capable of simulating disease progression, therapeutic response, treatment-related toxicity, recurrence, metastatic dissemination, and survival.[21]

Unlike conventional predictive models, digital twins continuously update their computational representations as new multimodal biomedical information becomes available. Integration of imaging, molecular biology, pathology, and clinical intelligence enables virtual patients to simulate dynamic tumor evolution, immune remodeling, stromal adaptation, angiogenesis, and therapeutic resistance at unprecedented biological resolution. These intelligent virtual patients allow clinicians to evaluate multiple therapeutic

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1227

strategies before implementation, optimize treatment sequencing, anticipate mechanisms of therapeutic resistance, and personalize supportive care according to evolving patient biology.

By combining multimodal biomedical intelligence with predictive simulation, digital twins transform computational oncology from retrospective analysis toward proactive precision medicine supported by continuously adaptive virtual patient ecosystems.

11. Intelligent Clinical Decision Support

Foundation AI models provide the computational infrastructure for next-generation clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered recommendations. Rather than interpreting radiological imaging, digital pathology, molecular diagnostics, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines independently, these models synthesize diverse biomedical information into unified computational representations supporting multidisciplinary oncology practice.[22]

Interactive clinical dashboards generate individualized diagnostic summaries, multimodal biomarker analyses, molecular interpretations, digital twin simulations, therapeutic recommendations, toxicity estimates, recurrence probabilities, disease progression forecasts, and survival predictions while facilitating collaboration among oncologists, radiologists, pathologists, surgeons, radiation oncologists, molecular biologists, pharmacists, nurses, genetic counselors, and computational scientists.

These intelligent systems improve workflow efficiency, strengthen multidisciplinary communication, reduce information fragmentation, and promote evidence-based personalized cancer management throughout the cancer care continuum.

12. Continuous Learning and Adaptive Multimodal Intelligence

A defining characteristic of multimodal foundation AI models is their ability to continuously evolve as new biomedical information becomes available. Artificial intelligence incorporates serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining predictive accuracy throughout the patient's clinical journey.[23]

Continual learning algorithms enable incremental refinement of computational knowledge without catastrophic forgetting of previously acquired information, while reinforcement learning optimizes therapeutic recommendations through iterative evaluation of treatment outcomes. Consequently, multimodal oncology platforms remain synchronized with evolving tumor biology, emerging scientific discoveries, changing clinical guidelines, and diverse patient trajectories. This adaptive computational paradigm transforms oncology into a continuously learning healthcare ecosystem capable of supporting real-time personalized precision medicine.

13. Federated Multimodal Learning Networks

Development of highly generalizable multimodal foundation AI models requires access to diverse biomedical datasets representing multiple healthcare systems, imaging platforms, pathology laboratories, molecular technologies, treatment protocols, and patient populations. Federated learning enables collaborative development of foundation AI models while preserving patient privacy and institutional governance through decentralized computational training.[24]

Participating healthcare institutions independently train local multimodal models using radiological imaging, digital pathology, genomics, transcriptomics, laboratory investigations, wearable monitoring, liquid biopsy, electronic health records, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. This collaborative learning strategy substantially improves algorithm robustness, fairness, external validity, and generalizability across diverse healthcare environments.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1227

Federated multimodal oncology ecosystems therefore establish international computational oncology networks capable of accelerating scientific discovery, improving equitable access to precision medicine, and supporting global cancer research while maintaining responsible biomedical data stewardship.

14. Explainability, Validation, and Ethical Governance

Successful implementation of multimodal learning in precision oncology requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting clinician confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, cross-modal attention visualization, and counterfactual explanations identifying the imaging, molecular, pathological, physiological, and clinical variables responsible for predictive outputs.[25]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible implementation further depends upon protection of patient privacy, informed consent, transparency, accountability, equitable access, responsible data governance, and continuous post-deployment surveillance to ensure trustworthy integration of intelligent computational systems into routine oncology practice.

15. Future Perspectives

Future multimodal oncology ecosystems will increasingly integrate multimodal foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, single-cell sequencing, liquid biopsy, quantum computing, Internet of Medical Things (IoMT), robotics, and cloud-native healthcare infrastructure into unified precision oncology platforms.[26]

These next-generation computational ecosystems will continuously integrate molecular biology, radiological imaging, digital pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, and real-world clinical outcomes while autonomously coordinating diagnostic workflows, optimizing therapeutic strategies, supporting adaptive clinical trials, generating personalized patient communication, and continuously synthesizing biomedical evidence.

Such intelligent multimodal ecosystems are expected to transform oncology from fragmented and reactive disease management toward predictive, preventive, adaptive, continuously learning, and precision-guided healthcare across the global cancer community.

16. Discussion

Artificial Multimodal learning represents one of the most significant paradigm shifts in computational oncology by integrating radiological imaging, molecular biology, digital pathology, laboratory biomarkers, wearable technologies, digital twins, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting comprehensive personalized cancer care. Unlike conventional artificial intelligence systems developed for isolated predictive tasks, multimodal foundation AI models simultaneously analyze complementary biomedical modalities to generate holistic computational representations of evolving cancer biology.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, digital twins, precision immunotherapy, adaptive therapeutics, continuous learning, federated collaboration, digital health, survivorship management, and intelligent clinical decision support demonstrate the extraordinary potential of multimodal artificial intelligence to redefine future oncology. Nevertheless, successful implementation requires continued advances in

DOI : https://doi.org/10.65713/ijaraiv14i1227

multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, and sustained multidisciplinary collaboration.
As biomedical knowledge and healthcare data continue to expand exponentially, multimodal learning is expected to become a central computational infrastructure supporting clinically translatable precision oncology worldwide.

17. Conclusion

Multimodal learning is transforming precision oncology by bridging radiological imaging, molecular biology, digital pathology, laboratory biomarkers, wearable technologies, electronic health records, digital twins, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting accurate diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive disease monitoring, and personalized cancer care throughout the disease continuum.[28]
Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning, reinforcement learning, digital twins, multimodal large language models, agentic AI, and generative artificial intelligence are expected to further strengthen intelligent oncology ecosystems, enabling increasingly accurate molecular characterization, predictive clinical decision-making, adaptive therapeutics, continuous disease surveillance, and continuously personalized oncology care.[29]
Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, molecular biologists, biomedical engineers, computer scientists, healthcare organizations, policymakers, industry partners, and regulatory agencies will accelerate the responsible implementation of multimodal learning in precision oncology. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, reduce disparities in cancer care, accelerate translational research, and establish a new era of intelligent, adaptive, and continuously learning precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Dr. RajathaMaradiHemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18
3. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
4. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14
5. Dr. RajathaMaradiHemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16
6. Joshi, A. et al. (2023) ‘Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis’, npj Precision Oncology, 7(1), p. 28.
7. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to

Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312, DOI: https://doi.org/10.46121/pspc.52.4.13.
8. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
9. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
10. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
11. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
12. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
13. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
14. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
15. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
16. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
17. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
18. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
19. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
20. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.
21. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881
22. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
23. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv. 2020. Doi:10.48550/arXiv.2010.11929.
24. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321, DOI: https://doi.org/10.46121/pspc.51.4.4
25. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304, DOI: https://doi.org/10.46121/pspc.51.2.7
26. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
27. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI

MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323, DOI: https://doi.org/10.46121/pspc.51.4.5

28. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303, DOI: https://doi.org/10.46121/pspc.52.1.5

29. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324, DOI: https://doi.org/10.46121/pspc.52.2.14

30. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12